Figure 3.

OR from network meta-analyses for stroke or systemic embolism and major bleeding for all pairwise comparisons. (Results between individual treatments, especially newer oral anticoagulants, should be interpreted with caution, given the limitations associated with using a fixed-effects model. See online supplementary appendix 9 for additional details.) ORs for recurrence of stroke or systemic embolism are below the diagonal (row-defining treatment vs column-defining treatment) and those for major bleeding are above the diagonal and in blue (column-defining treatment vs row-defining treatment). To obtain ORs for comparisons in the opposite direction, reciprocals should be taken (eg, the OR for standard dose warfarin compared with apixaban 5 mg twice daily for stroke or systemic embolism is 1/0.78=1.28). Significant results are in bold. VKA, vitamin K antagonist.